Hepatitis C Treatment Options - Valeant Pharmaceuticals

Valeant Pharmaceuticals
Forbes - ThinkEquity Partners reiterated a "sell" rating on Valeant Pharmaceuticals International after the drugmaker announced disappointing results for experimental hepatitis C drug Viramidine. Valeant (nyse: VRX - news - people ) said early Tuesday that

Aethlon Medical Presentation to be Web-cast at 4:20pm (EST) Today
Genetic Engineering News - Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic

ViroPharma's Generic Discount
Motley Fool - Now selling at a HUGE discount to its net asset value and an 8% dividend all in one incredibly rock-solid investment! Get the exclusive details in The Motley Fool s brand new Special Report, The ONE STOCK You Must Buy Now for Your IRA

Human Genome Sciences
Forbes - Piper Jaffray maintained an "outperform" rating on Human Genome Sciences and advised investors to buy on recent weakness in the stock. Shares of Human Genome Sciences (nasdaq: HGSI - news - people ) plunged 20% last Tuesday after the biotech firm